What types of MS does Ocrevus treat?

Ocrevus (ocrelizumab) is the first FDA-approved treatment for primary progressive multiple sclerosis (PPMS). It is also approved for relapsing forms of multiple sclerosis (RMS), including:

• Relapsing-remitting MS (RRMS) – Characterized by episodes of new or worsening symptoms (relapses) followed by periods of recovery.
• Secondary progressive MS (SPMS) with relapses – A stage where symptoms progressively worsen, with ongoing relapses.

Understanding Multiple Sclerosis (MS)

Multiple sclerosis (MS) is a chronic autoimmune disease where the immune system attacks the myelin sheath, the protective layer around nerve cells in the brain, spinal cord, and optic nerves. This leads to inflammation, nerve damage, and symptoms such as:

• Muscle weakness
• Fatigue
• Vision problems
• Difficulty with coordination and balance

Relapsing forms of MS (RMS) include people with relapsing-remitting MS (RRMS) and people with secondary progressive MS (SPMS) who continue to experience relapses. RRMS is the most common form of the disease and is characterized by episodes of new or worsening signs or relapses followed by periods of recovery. Most people with RRMS will eventually transition to SPMS, in which they experience steadily worsening disability over time.

Primary progressive MS (PPMS) is a debilitating form of the disease marked by steadily worsening symptoms but typically without distinct relapses or periods of remission. Approximately 15 percent of people with MS are diagnosed with the primary progressive form of the disease.

Related questions

• What are monoclonal antibodies?
• Is Kesimpta better than Ocrevus?
• How much does Ocrevus cost?

How Does Ocrevus Work?

Ocrevus is a humanized monoclonal antibody that targets CD20-positive B cells, which contribute to myelin damage in MS. By binding to CD20 proteins on these B cells, Ocrevus helps reduce disease activity while preserving other immune functions.

Clinical Evidence

In the Phase III ORATORIO trial, Ocrevus was shown to:

• Slow disability progression in PPMS patients.
• Reduce brain lesions (MRI-detected signs of disease activity) compared to a placebo over a median follow-up of three years.

How Is Ocrevus Administered?

Ocrevus is given as an intravenous (IV) infusion every six months:

• The first dose is split into two infusions, two weeks apart.
• Subsequent doses are given every six months.

A separate product, called Ocrevus Zunovo, is given as an injection under the skin once every 6 months.

Side Effects

Common side effects include:

• Infusion reactions (such as rash, fever, or shortness of breath).
• Upper respiratory tract infections.

This is not all the information you need to know about Ocrevus (ocrelizumab) for safe and effective use and does not take the place of your doctor’s directions. Review the full product information and discuss this information and any questions you have with your doctor or other health care provider.